<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39873469</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>[Tolvaptan versus fluid restriction in the treatment of hyponatremia due to inappropriate antidiuretic hormone secretion: efficacy and safety analysis in a cohort study].</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>144</EndPage><MedlinePgn>137-144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20960/nh.05558</ELocationID><Abstract><AbstractText>Background and objectives: hyponatremia is a common in older and hospitalized patients, often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study compares the efficacy and safety of tolvaptan versus fluid restriction in patients with hyponatremia and SIADH. Materials and methods: an observational cohort study was conducted with 186 patients with hyponatremia (Na+ &lt; 135 mmol/L) due to SIADH, treated at the Hospital Universitario de Pontevedra between 2015 and 2022. Of these, 86 were treated with tolvaptan (mean dose of 7.5 mg) and 100 with fluid restriction (1 liter of fluids per day). The primary endpoint was the normalization of sodium levels (Na &#x2265; 135 mmol/L). Results: tolvaptan was more effective than fluid restriction in correcting hyponatremia, increasing plasma sodium from 125.09 to 135.69 mmol/L in 4 days, compared to an increase from 126.44 to 130.5 mmol/L in 8 days with fluid restriction (p &lt; 0.001). Mortality at 60 days was lower in the tolvaptan group (12.8 % vs. 32.8 %, p &lt; 0.003). However, tolvaptan showed higher risks of sodium overcorrection (10.46 %) and polyuria (5.81 %), while fluid restriction was associated with greater dehydration, headache, and cramps. Conclusion: tolvaptan corrects hyponatremia more quickly and effectively than fluid restriction, although with a higher risk of overcorrection and polyuria, and is associated with lower 60-day mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez Gonz&#xe1;lez</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n. Hospital Universitario Montecelo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Nunes</LastName><ForeName>Manuella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Enfermer&#xed;a. Hospital Universitario Montecelo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodeiro Escobar</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. &#xc1;rea Sanitaria de Vigo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ll&#xf3;piz Castedo</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. &#xc1;rea Sanitaria de Vigo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruades Pati&#xf1;o</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de Enfermer&#xed;a. Hospital Universitario Montecelo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva Sousa</LastName><ForeName>Joana Isabel</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. &#xc1;rea Sanitaria de Pontevedra e O Saln&#xe9;s.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez Pulian</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. &#xc1;rea Sanitaria de Pontevedra e O Saln&#xe9;s.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieiro Pe&#xf1;a</LastName><ForeName>Camila</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. &#xc1;rea Sanitaria de Pontevedra e O Saln&#xe9;s.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez Casti&#xf1;eira</LastName><ForeName>Thal&#xed;a Chantal</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Familiar y Comunitaria. Complejo Hospitalario Universitario de Pontevedra.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Gonz&#xe1;lez</LastName><ForeName>Mar&#xed;a Inmaculada</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Unidad de Enfermer&#xed;a. Hospital &#xc1;lvaro Cunqueiro.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Tolvapt&#xe1;n versus restricci&#xf3;n h&#xed;drica en el tratamiento de la hiponatremia por secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica: an&#xe1;lisis de eficacia y seguridad en un estudio de cohortes.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>21G72T1950</RegistryNumber><NameOfSubstance UI="D000077602">Tolvaptan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065092">Antidiuretic Hormone Receptor Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="Y">Hyponatremia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077602" MajorTopicYN="Y">Tolvaptan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="Y">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065092" MajorTopicYN="Y">Antidiuretic Hormone Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="Y">Fluid Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Antecedentes y objetivos: la hiponatremia es com&#xfa;n en pacientes mayores y hospitalizados, frecuentemente causada por el s&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica (SIADH). Este estudio compara la eficacia y seguridad de tolvapt&#xe1;n frente a la restricci&#xf3;n h&#xed;drica en pacientes con hiponatremia y SIADH. Material y m&#xe9;todos: se realiz&#xf3; un estudio observacional de cohortes con 186 pacientes con hiponatremia (Na+ &lt; 135 mmol/L) por SIADH, tratados en el Complejo Hospitalario de Pontevedra entre 2015 y 2022. De ellos, 86 fueron tratados con tolvapt&#xe1;n (dosis media de 7,5 mg) y 100 con restricci&#xf3;n h&#xed;drica (1 litro de l&#xed;quidos al d&#xed;a). El objetivo principal fue la normalizaci&#xf3;n de los niveles de sodio (Na &#x2265; 135 mmol/L). Resultados: Tolvapt&#xe1;n fue m&#xe1;s eficaz que la restricci&#xf3;n h&#xed;drica en la correcci&#xf3;n de la hiponatremia, aumentando el sodio plasm&#xe1;tico de 125,09 a 135,69 mmol/L en 4 d&#xed;as, frente a un aumento de 126,44 a 130,5 mmol/L en 8 d&#xed;as para la restricci&#xf3;n h&#xed;drica (p &lt; 0,001). La mortalidad a los 60 d&#xed;as fue menor en el grupo de tolvapt&#xe1;n (12,8 % vs. 32,8 %, p &lt; 0,003). Sin embargo, tolvapt&#xe1;n mostr&#xf3; mayores riesgos de hipercorrecci&#xf3;n del sodio (10,46 %) y poliuria (5,81 %), mientras que la restricci&#xf3;n h&#xed;drica se asoci&#xf3; con mayor deshidrataci&#xf3;n, cefalea y calambres. Conclusi&#xf3;n: tolvapt&#xe1;n corrige la hiponatremia m&#xe1;s r&#xe1;pido y eficazmente que la restricci&#xf3;n h&#xed;drica, aunque con mayor riesgo de hipercorrecci&#xf3;n y poliuria, adem&#xe1;s de asociarse con una menor mortalidad a 60 d&#xed;as.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica. Hiponatremia. Tolvapt&#xe1;n. Restricci&#xf3;n h&#xed;drica.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>21</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>28</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>28</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39873469</ArticleId><ArticleId IdType="doi">10.20960/nh.05558</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35659417</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Syndrome of inappropriate antidiuretic hormone secretion.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>146</EndPage><MedlinePgn>139-146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2022.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(22)00143-9</ELocationID><Abstract><AbstractText>Hyponatremia is the most frequent electrolytic disorder in hospitalized patients, and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), the most frequent cause of hiponatremia with clinically normal extracellular volume. It consists of a disorder of the regulation of body water that obeys to different causes, mainly cancer, pulmonary illnesses, disorders of the central nervous system and diverse drugs. As in any hiponatremia it a physiological knowledge of the regulation of body water and sodium is essential as well as the application of precise diagnostic criteria in order to manage the problem with an effective treatment. The available data until the moment show that the clinical diagnosis of SIADH made by professionals is mainly not supported on the established criteria drawn by experts and this lack of accuracy probably hits in the therapeutic result. The basis of the treatment of the SIADH is to correct its cause, water restriction, solutes (sodium chloride) and the use of vaptans in case of failure of the previous measures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poch</LastName><ForeName>Esteban</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a y Trasplante Renal, Hospital Cl&#xed;nic, Barcelona, Espa&#xf1;a; IDIBAPS; Departamento de Medicina, Universidad de Barcelona, Barcelona, Espa&#xf1;a. Electronic address: epoch@clinic.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a y Trasplante Renal, Hospital Cl&#xed;nic, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;eiro</LastName><ForeName>Gast&#xf3;n</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a y Trasplante Renal, Hospital Cl&#xed;nic, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11000-17-2</RegistryNumber><NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance></Chemical><Chemical><RegistryNumber>451W47IQ8X</RegistryNumber><NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="Y">Hyponatremia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="Y">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012965" MajorTopicYN="N">Sodium Chloride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014667" MajorTopicYN="N">Vasopressins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidiuretic hormone</Keyword><Keyword MajorTopicYN="N">Hiponatremia</Keyword><Keyword MajorTopicYN="N">Hormona antidiur&#xe9;tica</Keyword><Keyword MajorTopicYN="N">Hyponatremia</Keyword><Keyword MajorTopicYN="N">Sodio</Keyword><Keyword MajorTopicYN="N">Sodium</Keyword><Keyword MajorTopicYN="N">Vaptanes</Keyword><Keyword MajorTopicYN="N">Vaptans</Keyword><Keyword MajorTopicYN="N">Vasopresina</Keyword><Keyword MajorTopicYN="N">Vasopressin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>10</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35659417</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2022.02.015</ArticleId><ArticleId IdType="pii">S0025-7753(22)00143-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31627961</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>154</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Syndrome of inappropriate antidiuretic hormone secretion in a patient with diffuse large B-cell lymphoma.</ArticleTitle><Pagination><StartPage>473</StartPage><MedlinePgn>473</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2019.06.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(19)30539-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Navarro-Almenzar</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a y Hemoterapia, Hospital Cl&#xed;nico Universitario Virgen de la Arrixaca, Murcia, Espa&#xf1;a. Electronic address: b.almenzar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caba&#xf1;as Perianes</LastName><ForeName>Valent&#xed;n</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a y Hemoterapia, Hospital Cl&#xed;nico Universitario Virgen de la Arrixaca, Murcia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica en paciente con linfoma difuso de c&#xe9;lulas grandes B.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11000-17-2</RegistryNumber><NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="Y">Hyponatremia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="Y">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014667" MajorTopicYN="N">Vasopressins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31627961</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2019.06.031</ArticleId><ArticleId IdType="pii">S0025-7753(19)30539-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31167725</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Season>Jun-Jul</Season></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Syndrome of inappropriate antidiuretic hormone secretion following transarterial chemoembolisation of hepatocellular carcinoma.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>398</EndPage><MedlinePgn>397-398</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2018.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(18)30149-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yebra Carmona</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Espa&#xf1;a. Electronic address: yebra.jorge@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaquotot Herranz</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavecchia</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo Grau</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica postquimioembolizaci&#xf3;n transarterial de un carcinoma hepatocelular.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077330">Saline Solution</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016461" MajorTopicYN="N">Chemoembolization, Therapeutic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="N">Hyponatremia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="N">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009994" MajorTopicYN="N">Osmolar Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077330" MajorTopicYN="N">Saline Solution</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31167725</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2018.05.018</ArticleId><ArticleId IdType="pii">S0210-5705(18)30149-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30125258</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0025-7680</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>[Prostate carcinoma and syndrome of inappropriate antidiuretic hormone secretion].</ArticleTitle><Pagination><StartPage>290</StartPage><EndPage>293</EndPage><MedlinePgn>290-293</MedlinePgn></Pagination><Abstract><AbstractText>Prostate cancer is an extremely rare cause of syndrome of inappropriate antidiuretic hormone (SIADH) secretion. These tend to be aggressive tumors and SIADH can carry serious clinical consequences. A 64 years old patient was diagnosed with Gleason 4+3: 7 prostate adenocarcinoma in December 2014 and received hormonal blockade therapy. By March 2015 he was admitted for symptomatic hyponatremia and SIADH secretion was diagnosed, with no other probable cause than prostate cancer. He suffered a rapid progression of his oncologic disease, surprisingly with PSA in normal range, and died in the short term. There is great clinical and histopathological variability in the cases reported in the literature of association of prostate carcinoma and SIADH. However, they all agree on the aggressiveness of these tumors. This characteristic is present in tumors that have neuroendocrine features. They are frequently resistant to hormonal treatment and may present with paraneoplastic syndromes such as SIADH. The profile of its molecular alterations is under study for the development of target therapies. The association of prostate adenocarcinoma and SIADH is very uncommon and could involve neuroendocrine differentiation. For this reason, it is essential to perform a new biopsy of the tumor or its metastases at the progressive disease in order to conduct an appropriate treatment according to its morphological, immunohistochemical and, in the future, molecular characteristics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miretti</LastName><ForeName>Virginia S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a, Hospital Universitario Privado de C&#xf3;rdoba, Argentina. E-mail: virginiamiretti85@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila</LastName><ForeName>Rodolfo A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a, Hospital Universitario Privado de C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>Jerem&#xed;as T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a, Hospital Universitario Privado de C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Servicio de Oncolog&#xed;a, Hospital Universitario Privado de C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labori&#xe9;</LastName><ForeName>Mar&#xed;a Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Servicio de Anatom&#xed;a Patol&#xf3;gica, Hospital Universitario Privado de C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Carcinoma de pr&#xf3;stata y s&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="N">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neuroendocrine carcinoma of the prostate</Keyword><Keyword MajorTopicYN="N">prostate carcinoma</Keyword><Keyword MajorTopicYN="N">syndrome of inappropriate antidiuretic hormone secretion (SIADH)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30125258</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28946972</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1989-2284</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia</Title><ISOAbbreviation>Nefrologia</ISOAbbreviation></Journal><ArticleTitle>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.</ArticleTitle><Pagination><StartPage>558</StartPage><EndPage>559</EndPage><MedlinePgn>558-559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nefro.2016.10.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0211-6995(16)30188-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carre&#xf1;o</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a, Hospital General Universitario de Ciudad Real, SESCAM, Ciudad Real, Espa&#xf1;a. Electronic address: acarreno@senefro.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a, Hospital General Universitario de Ciudad Real, SESCAM, Ciudad Real, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayoralas</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a, Hospital General Universitario de Ciudad Real, SESCAM, Ciudad Real, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calle</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a, Hospital General Universitario de Ciudad Real, SESCAM, Ciudad Real, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de secreci&#xf3;n inadecuada de hormona antidiur&#xe9;tica (SIADH) secundario a bortezomib en mieloma m&#xfa;ltiple de cadenas ligeras. Tratamiento con tolvapt&#xe1;n.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nefrologia</MedlineTA><NlmUniqueID>8301215</NlmUniqueID><ISSNLinking>0211-6995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065092">Antidiuretic Hormone Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007147">Immunoglobulin Light Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>21G72T1950</RegistryNumber><NameOfSubstance UI="D000077602">Tolvaptan</NameOfSubstance></Chemical><Chemical><RegistryNumber>69G8BD63PP</RegistryNumber><NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065092" MajorTopicYN="N">Antidiuretic Hormone Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007147" MajorTopicYN="N">Immunoglobulin Light Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007177" MajorTopicYN="N">Inappropriate ADH Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077602" MajorTopicYN="N">Tolvaptan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28946972</ArticleId><ArticleId IdType="doi">10.1016/j.nefro.2016.10.015</ArticleId><ArticleId IdType="pii">S0211-6995(16)30188-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>